BioCentury
ARTICLE | Product Development

Sorting through the ReoPro data

September 3, 1996 7:00 AM UTC

A mixed bag of data on Centocor Inc. 's ReoPro anti-platelet antibody was disclosed last week at the European Society of Cardiology meeting in Birmingham, U.K. The news, combined with analyst interpretations, sent CNTO stock down $1.50 to $33.875.

On the plus side, long-term data from the company's pivotal EPIC trial in high-risk angioplasty (PTCA) patients showed that ReoPro prevented 23 percent of complications at six months. At one year, ReoPro provided a 20 percent reduction in complications. At two years the drug provided a 14 percent reduction in complications; and at three years the reduction was 13 percent...